Essa Pharma signs agreement to purchase Realm Therapeutics

On May 16, 2019, ESSA Pharma Inc. (“ESSA”) (TSX-V: EPI; NASDAQ: EPIX) and Realm Therapeutics plc (“Realm”) (NASDAQ: RLM) announced that they entered into a definitive agreement whereby ESSA would acquire all of the issued and outstanding shares of Realm in an all-share transaction. The acquisition, which remains subject to the approval of Realm’s shareholders, is intended to be implemented by means of a United Kingdom court-sanctioned scheme of arrangement, and is expected to be completed by the middle of 2019. Fasken acted as Canadian counsel to Realm, with a team comprised of Jay Lefton (Corporate), Myroslav Chwaluk (Corporate), Ryan Schnier (Corporate), Armand Benitah (Intellectual Property), Christopher Steeves (Tax), Timothy Squire (Regulatory), Karen Sargeant (Labour and Employment) and Ross Gascho (Benefits).